vTv Therapeutics to Present a Poster at the American Diabetes Association's 78th Scientific Sessions | Financial Buzz

vTv Therapeutics to Present a Poster at the American Diabetes Associations 78th Scientific Sessions

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease, diabetes and other
therapeutic areas, today announced that Company management will present
a poster featuring vTv Therapeutics’ liver-selective Glucokinase
Activator at the American Diabetes Association’s 78th Scientific
Sessions held in Orlando, Fla., June 22–26, 2018.

Details of the presentations are listed below:

Late-Breaking Poster Title: “Simplici-T1 First Clinical Trial to
Test Activation of Glucokinase as an Adjunctive Treatment for Type 1
Diabetes”Poster Number: 126-LBCategory:
12-E Clinical Therapeutics/New Technology–Oral AgentsDate and
Time: Monday, June 25, 2018, 12-1 pm ET“As the
first company to evaluate a Glucokinase Activator in people with type 1
diabetes, we are very excited to be sharing this clinical data at the
American Diabetes Association’s 78th Scientific Sessions,”
said Carmen Valcarce, Ph.D., executive vice president, chief scientific
officer, vTv Therapeutics. “TTP399 was well tolerated in this small,
open label, study in patients with type 1 diabetes and showed trends
towards improving glycemic control while reducing insulin dose.
Following these encouraging data, we are now evaluating TTP399 in a
12-week randomized, placebo-controlled, phase 2 study in type 1 diabetes
to evaluate safety and efficacy”.

About Simplici-T1

Simplici-T1 is a multi-center, randomized, double-blind, adaptive study
assessing the pharmacokinetics, pharmacodynamics, safety and
tolerability of TTP399 in adult patients with type 1 diabetes (T1D).
This study is being conducted in two phases: Phase 1 evaluated the
safety of ascending TTP399 dosage regimens in five patients each over
one week of daily dosing; Phase 2 will evaluate the safety and efficacy
of a TTP399 dosing regimen over twelve weeks of daily dosing. This study
is being conducted with support from JDRF, the leading global
organization funding T1D research.

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which a person’s pancreas
stops producing insulin, a hormone that enables people to get energy
from food. It occurs when the body’s immune system attacks and destroys
the insulin-producing cells in the pancreas, called beta cells. While
its causes are not yet entirely understood, scientists believe that both
genetic factors and environmental triggers are involved. Its onset has
nothing to do with diet or lifestyle. There is nothing you can do to
prevent T1D, and—at present—nothing you can do to cure it.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and diabetes as well as treatment of
inflammatory disorders.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005231/en/